Pazopanib Hydrochloride
FDA Approved: * October 19, 2023Pharm Company: * APOTEX
Category: Cancer
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.[3][4][5][6] Contents 1 Medical uses 2 Contraindications 3 Adverse effec... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.